Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Why should I use sharewise

Quidel Corp. Stock

Price
Target price
€212.00

€212.00

5.940%
14.0
5.940%
€198.00

€198.00

 
Latest predictions
-
02.07.20
buy
-
28.06.20
buy
-
28.06.20
buy
€198.00
15.06.20
buy
Your prediction

Quidel Corp. Stock

Quidel Corp. dominated the market today, gaining €14.00 (5.940%).
Currently there is a rather positive sentiment for Quidel Corp. with 4 Buy predictions and 0 Sell predictions.
However, we have a potential of -6.604% for Quidel Corp. as the target price of €198.00 is below the current price of €212.00.
Register To Post

Other discussions about Quidel Corp. Stock

New thread

News

Quidel Receives BARDA Funding to Develop Point-of-Care Diagnostic Assay That Includes COVID-19


Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has

Quidel Announces Jack Schuler Will Retire From Quidel’s Board of Directors


Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Jack W. Schuler

Quidel Receives Amended Emergency Authorization for Rapid Antigen COVID-19 Diagnostic Assay Using Sofia 1 Instrument


Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has

Quidel to Present Virtually at William Blair 40th Annual Growth Stock Conference


Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the

Quidel’s Lyra® Direct SARS-CoV-2 Assay Receives Emergency Use Authorization and CE Mark for Molecular Detection of COVID-19, Without Extraction Step


Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has

Quidel Receives Emergency Authorization for Rapid Antigen COVID-19 Diagnostic Assay


Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has

Quidel Reports First Quarter 2020 Financial Results


Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the first

Quidel to Present Virtually at the BofA Securities 2020 Health Care Conference


Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the

Quidel’s Lyra® Direct SARS-CoV-2 Assay Submitted for Emergency Use Authorization for Molecular Detection of COVID-19, Without Extraction Step


Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has

Quidel to Hold First Quarter 2020 Financial Results Conference Call on May 6th, 2020


Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report first quarter 2020 financial

Quidel’s Lyra® SARS-CoV-2 Assay Receives Authorization for Expanded Use for Molecular Detection of COVID-19; Also Receives CE Mark, Health Canada Authorization


Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel’s Lyra®

Quidel Receives Emergency Use Authorization for Molecular COVID-19 Diagnostic Assay


Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has

Quidel to Present at Upcoming Conferences


Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the

Quidel Reports Fourth Quarter and Full Year 2019 Financial Results


Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the

Quidel to Hold Fourth Quarter and Full Year 2019 Financial Results Conference Call on February 12th, 2020


Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report fourth quarter and full year 2019

Quidel Announces Preliminary Revenue for Fourth Quarter 2019


Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it expects